The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Catalyst Biosciences, Inc. (CBIO) been one of those ...

Catalyst Biosciences, Inc. (CBIO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement fa ...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today published a detailed investor presentation in advance ...

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year ...

Catalyst Biosciences Inc CBIO shares are soaring Tuesday morning after GC Biopharma signed an Asset Purchase Agreement with the company late Monday. What Happened: GC Biopharma signed an agreement ...

Catalyst Biosciences, Inc. Company to Announce a Record Date for Initial Distribution in Due Course. SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc ...

Source: Catalyst Biosciences (as of June 30, 2018) In the first six months of 2018, Catalyst spent about USD 7.7mn. on R&D and USD 6.1mn. on G&A, bringing expenses to a total of USD 13.8mn.

Oct 24 (Reuters) - Catalyst Biosciences Inc: * Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the ...

* Catalyst plans to initiate clinical pivotal trial in hemophilia A and B "inhibitor" patients in 2017 * Catalyst Biosciences Inc says remain on track to initiate Phase 2/3 clinical pivotal trial ...

Investors: Andrew McDonald Managing Director LifeSci Advisors, LLC 646.597.6987 [email protected] Fletcher Payne, CFO Catalyst Biosciences, Inc. 650.871.0761 [email protected] Media ...

Source: Catalyst Biosciences (as of June 30, 2018) In the first six months of 2018, Catalyst spent about USD 7.7mn. on R&D and USD 6.1mn. on G&A, bringing expenses to a total of USD 13.8mn.